Alex is Managing Director of Bamburgh Capital. He qualified as a chartered accountant with PricewaterhouseCoopers in 1998, joined Brewin Dolphin Securities in 2000 before becoming co-founder of Zeus Capital in 2003. Alex then went on to co-found Bamburgh Capital in 2011, executing over 20 transactions acting on both the “buy” and “sell” side and raising funding. During this time, Alex was co-founder of Compass BioScience Group Limited and Collbio, two highly acquisitive companies, and became interim CFO of Collbio which undertook an IPO on the London Stock Market within an 18-month period, changing its name to Collagen Solutions. Given Alex’s experience of public markets and growth capital investing, his expertise and knowledge are highly relevant to the ongoing success of the Company.
You should only rely on the information provided in the Prospectus and relevant Key Information Document when deciding whether to make an investment. Your capital is at risk and you may get back less than you invest.
Seneca Growth Capital VCT Plc (previously Hygea vct plc) is incorporated in England and Wales. The company’s main country of operation is the United Kingdom. The company is an alternative investment fund under the AIF Regulations 2013. Seneca Growth Capital VCT Plc’s registered office is at 9 The Parks, Haydock, Merseyside, WA12 0JQ (Company No. 04221489). Seneca Partners Limited (Company No. 07196273) is Authorised and Regulated by the Financial Conduct Authority (FRN 583361). Seneca Partners Limited’s registered office is at 9 The Parks, Haydock, WA12 0JQ.